Behavioral Finance

May 17, 2026

Infographic with four colored blocks labeled: Lucky (gray), Disciplined Investor (green), Confused (light gray), Bias-Trapped (orange).

The Ostrich Effect: Karlsson, Loewenstein & Seppi’s 2009 NBER Bias Behind Why Indian Investors Stop Checking Their Portfolios During Corrections

The Ostrich Effect — documented by Karlsson, Loewenstein & Seppi in 2009 — explains why Indian investors stop checking portfolios during market corrections. Brokerage logins fall 9.5% on down-1% days. We walk through the academic foundation, Indian SIP-discontinuation and demat-dormancy data, a seven-step counter-measure checklist, and Titan Biotech's FY25 disclosure architecture as an illustrative anti-ostrich case study.

May 17, 2026

Hero image: dark blue page with white 'Board Meeting Frequency' title, green subtitle, and a green timeline across FY21–FY25 showing milestones: Compliance, Disclosure, Audit clean, Board change, All boxes.

Board Meeting Frequency: SEBI LODR Regulation 17(2) and the Forensic Governance Engagement Test

Board meeting frequency is the cheapest forensic governance signal hidden in every Indian annual report. SEBI LODR Reg 17(2) sets the floor at 4, best-practice boards meet 8-12 times, and Titan Biotech FY25 illustrates the disciplined end with 14 meetings sitting alongside a fortress balance sheet.

May 16, 2026

Infographic-style hero showing four investor mindsets: Lucky (left, gray), Confused (left, light gray), Disciplined Investor (right, green), and Bias-Trapped (right, orange).

Myopic Loss Aversion (Benartzi & Thaler 1995): Why Indian Retail Investors Sabotage Long-Term Returns by Checking Portfolios Too Often

Myopic Loss Aversion — Benartzi & Thaler's 1995 Nobel-grade explanation of the equity premium puzzle, applied to Indian retail investors, with Titan Biotech FY25 audited numbers as an anti-MLA corporate-cadence case study.

May 16, 2026

Hero header: Net Debt to EBITDA Ratio with a green accent 'Manish Goel Portfolio Management Service' and a subtitle line on a dark blue background.

Net Debt to EBITDA Ratio: The Single Solvency Test Credit Analysts Care About Most

Net Debt to EBITDA is the single ratio professional credit analysts use most when assessing survival odds. This educational deep-dive teaches how to read it, where retail investors misinterpret it, and how Titan Biotech (BSE: 524717) FY25 audited numbers illustrate a -0.75x net-cash fortress reading. Not a buy/sell recommendation.